• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Wall Street Beat

Scilex touts data for novel lidocaine patch

December 5, 2016 By Sarah Faulkner

Scilex Pharmaceuticals

Sorrento Therapeutics (NSDQ:SRNE) subsidiary Scilex Pharmaceuticals said today that its lidocaine patch, ZTlido, met primary and secondary endpoints in a pivotal study comparing the patch to Endo Pharmaceutical‘s Lidoderm patch. The data will be used to resubmit a new drug application to the FDA in mid-2017, the Malvern, Pa.-based company said. The clinical trial evaluated Scilex’s […]

Filed Under: Clinical Trials, Featured, Food & Drug Administration (FDA), Pain Management, Pharmaceuticals, Wall Street Beat Tagged With: Endo Pharmaceuticals, Scilex Pharmaceuticals, Sorrento Therapeutics

InGeneron inks collaboration with German Accelerator Life Sciences

December 5, 2016 By Sarah Faulkner

InGeneron raises $20m in Series D for regenerative stem cell therapies

InGeneron said today that it landed a collaboration with the German Accelerator Life Sciences program, establishing an additional U.S. presence in Cambridge, Mass. The initiative is supported by the German Federal Ministry for Economic Affairs & Energy. The GALS program will provide InGeneron with a group of mentors to help leverage its network within the […]

Filed Under: Orthopedics, Regenerative Medicine, Stem Cells, Wall Street Beat, Wound Care Tagged With: German Accelerator Life Sciences, InGeneron

Pharma execs assess landscape under President Trump

December 2, 2016 By Sarah Faulkner

capitol hill

Executives from U.S. drugmakers such as Regeneron Pharmaceuticals and Pfizer talked about the possible changes awaiting the industry under President-elect Donald Trump at the Forbes Healthcare Summit this week. After he was elected, pharmaceutical stocks surged as investors concluded the threat of action on drug pricing had lessened. Trump has said he wants to repeal […]

Filed Under: Featured, Food & Drug Administration (FDA), Legal News, Pharmaceuticals, Policy, Wall Street Beat Tagged With: Allergan, Merck, Pfizer Inc., Regeneron

Senseonics, Roche expand distribution deal for Eversense glucose monitor

December 2, 2016 By Sarah Faulkner

Senseonics, Roche expand distribution deal for glucose monitor

Senseonics (NYSE:SENS) said today that it expanded its exclusive distribution agreement with Roche (PINK:RHHBY) for its implantable continuous glucose monitoring system for people with diabetes. The new agreement includes all of Europe, the Middle East and Africa, excluding Scandinavia, Finland and Israel. According to the agreement, Germantown, Maryland-based Senseonics has given Roche exclusive rights to promote, […]

Filed Under: Diabetes, Distribution, Featured, Wall Street Beat Tagged With: Roche, Senseonics

Hedge funds betting on J&J after Actelion remains silent on takeover bid

December 2, 2016 By Sarah Faulkner

Actelion, Johnson & Johnson

Despite reports this week that Actelion Pharmaceuticals (VTX:ATLN) rejected Johnson & Johson‘s (NYSE:JNJ) 2nd takeover bid, hedge funds are piling into the Swiss biotech firm, encouraged by Actelion’s silence on the matter. The 2 companies have been engaged in informal talks for 2 months, according to Reuters, and the latest offer was pegged at 250 Swiss francs per share. […]

Filed Under: Mergers & Acquisitions, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Actelion Pharmaceuticals, johnsonandjohnson

Mylan CEO Bresch accepts “full responsibility” for EpiPen price hikes

December 2, 2016 By Sarah Faulkner

Mylan

Mylan (NSDQ:MYL) CEO Heather Bresch reportedly accepted “full responsibility” for the company’s EpiPen price hikes that sparked outrage over the past 2 months, but defended the company’s actions while blaming an opaque industry that she said was not built for consumer engagement. The CEO made her remarks at the Forbes Healthcare Summit in New York on Thursday. “There are […]

Filed Under: Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Merck, Mylan

Actelion rejects J&J’s takeover offer

December 1, 2016 By Sarah Faulkner

Actelion, Johnson & Johnson

Swiss biotech firm Actelion Pharmaceuticals (VTX:ATLN) reportedly rejected Johnson & Johnson‘s (NYSE:JNJ) 2nd takeover offer, sending it shares down -6% in afternoon trading yesterday. The 2 companies have been engaged in informal talks for 2 months, according to Reuters, and the latest offer was pegged at 250 Swiss francs per share. J&J’s $270 billion bid for Actelion tempted shareholders, […]

Filed Under: Featured, Mergers & Acquisitions, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Actelion Pharmaceuticals, johnsonandjohnson

Report: J&J raises the stakes in Actelion pursuit

November 30, 2016 By Sarah Faulkner

Actelion, Johnson & Johnson

Johnson & Johnson (NYSE:JNJ) has reportedly raised its offer for Swiss biotech firm Actelion Pharmaceuticals (VTX:ATLN), pressuring the company to accept a takeover deal. The companies have been in talks for nearly 2 months but so far have not reached a deal, according to Reuters. The news outlet reported that Actelion wants J&J to become a major shareholder […]

Filed Under: Mergers & Acquisitions, Pharmaceuticals, Wall Street Beat Tagged With: Actelion Pharmaceuticals, johnsonandjohnson, Roche

Intec Pharma inks deal with Michael J. Fox Foundation for patient recruitment

November 28, 2016 By Sarah Faulkner

Intec Pharma

Intec Pharma (NSDQ:NTEC) said today that it inked a deal with the Michael J. Fox Foundation for Parkinson’s Research to support the biopharmaceutical company’s patient recruitment and retention for its pivotal phase III trial. The study will evaluate Intec Pharma’s lead candidate, the “accordion pill” carbidopa/levodopa (AP-CD/LD), as a treatment for patients with advanced Parkinson’s […]

Filed Under: Clinical Trials, Featured, Neurological, Pharmaceuticals, Wall Street Beat Tagged With: Intec Pharma

Catalent to float $400m debt offering

November 28, 2016 By Sarah Faulkner

Catalent

Catalent (NYSE:CTLT) said today that it plans to fund its acquisition of soft-gel pharmaceutical capsule manufacturer Accucaps Industries Ltd with a $400 million debt offering. The Somerset, N.J.-based company said the private placement offering of euro-dominated senior unsecured notes due in 2024 will also be used to repay some of the outstanding borrowings under its senior […]

Filed Under: Featured, Funding Roundup, Mergers & Acquisitions, Pharmaceuticals, Wall Street Beat Tagged With: Catalent

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 188
  • Page 189
  • Page 190
  • Page 191
  • Page 192
  • Page 193
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS